Tocotrienol as a potential anticancer agent

Carcinogenesis

Volumn 33, Issue 2, 2012, Pages 233-239

  Ling, Ming T ^a   Luk, Sze U ^b   Al Ejeh, Fares ^c   Khanna, Kum K ^c  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ALPHA TOCOTRIENOL; ATORVASTATIN; BORTEZOMIB; CELECOXIB; ERLOTINIB; GEFITINIB; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 24; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TAMOXIFEN; THALIDOMIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VIMENTIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER PREVENTION; CANCER SPECIFIC SURVIVAL; CANCER STEM CELL; CANCER THERAPY; CELL CYCLE G1 PHASE; CELL KILLING; CELL MIGRATION; CELL SURVIVAL; CHEMOPROPHYLAXIS; CHEMOSENSITIVITY; CHEMOSENSITIZATION; DENDRITIC CELL; DISEASE FREE SURVIVAL; DNA DAMAGE; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG SELECTIVITY; DRUG TARGETING; DRUG UPTAKE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSURVEILLANCE; LIPID PEROXIDATION; LIVER CANCER; LYMPHOCYTE PROLIFERATION; OXIDATIVE STRESS; PRIORITY JOURNAL; RADIATION PROTECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; SURVIVAL RATE; UPREGULATION;

EID: 84856582504     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr261     Document Type: Article

References (74)

1. Sen, C.K. et al. (2007) Tocotrienols: the emerging face of natural vitamin E. Vitam. Horm., 76, 203-261.
2. Theriault, A. et al. (1999) Tocotrienol: a review of its therapeutic potential. Clin. Biochem., 32, 309-319.
3. Traber, M.G. et al. (1995) Vitamin E: beyond antioxidant function. Am. J. Clin. Nutr., 62, 1501S-1509S.
4. Kayden, H.J. et al. (1993) Absorption, lipoprotein transport, and regulation of plasma concentrations of vitamin E in humans. J. Lipid. Res., 34, 343-358.
5. Nesaretnam, K. (2008) Multitargeted therapy of cancer by tocotrienols. Cancer Lett., 269, 388-395.
6. Yap, S.P. et al. (2001) Pharmacokinetics and bioavailability of alpha-, gamma- and delta-tocotrienols under different food status. J. Pharm. Pharmacol., 53, 67-71.
7. Ren, Z. et al. (2010) Dietary supplementation with tocotrienols enhances immune function in C57BL/6 mice. J. Nutr., 140, 1335-1341.
8. Heinonen, O.P. et al. (1998) Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J. Natl Cancer Inst., 90, 440-446.
9. Murtaugh, M.A. et al. (2004) Antioxidants, carotenoids, and risk of rectal cancer. Am. J. Epidemiol., 159, 32-41.
10. Lee, I.M. et al. (2005) Vitamin E in the primary prevention of cardiovascular disease and cancer: theWomen#s Health Study: a randomized controlled trial. JAMA, 294, 56-65.
11. Lippman, S.M. et al. (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA, 301, 39-51.
12. Ju, J. et al. (2010) Cancer-preventive activities of tocopherols and tocotrienols. Carcinogenesis, 31, 533-542.
13. Sylvester, P.W. et al. (2010) The value of tocotrienols in the prevention and treatment of cancer. J. Am. Coll. Nutr., 29, 324S-333S.
14. Sundram, K. et al. (1989) Effect of dietary palm oils on mammary carcinogenesis in female rats induced by 7,12-dimethylbenz(a)anthracene. Cancer Res., 49, 1447-1451.
15. Gould, M.N. et al. (1991) A comparison of tocopherol and tocotrienol for the chemoprevention of chemically induced rat mammary tumors. Am. J. Clin. Nutr., 53, 1068S-1070S.
16. Ngah, W.Z. et al. (1991) Effect of tocotrienols on hepatocarcinogenesis induced by 2-acetylaminofluorene in rats.Am. J.Clin. Nutr., 53, 1076S-1081S.
17. Iqbal, J. et al. (2004) Suppression of diethylnitrosamine and 2-acetylaminofluorene-induced hepatocarcinogenesis in rats by tocotrienol-rich fraction isolated from rice bran oil. Eur. J. Cancer Prev., 13, 515-520.
18. Rahmat, A. et al. (1993) Long-term administration of tocotrienols and tumor-marker enzyme activities during hepatocarcinogenesis in rats. Nutrition, 9, 229-232.
19. Wada, S. et al. (2005) Tumor suppressive effects of tocotrienol in vivo and in vitro. Cancer Lett., 229, 181-191.
20. Barve, A. et al. (2010) Mixed tocotrienols inhibit prostate carcinogenesis in TRAMP mice. Nutr. Cancer, 62, 789-794.
21. Takahashi, S. et al. (2009) Suppression of prostate cancer in a transgenic rat model via gamma-tocopherol activation of caspase signaling. Prostate, 69, 644-651.
22. Barve, A. et al. (2009) Gamma-tocopherol-enriched mixed tocopherol diet inhibits prostate carcinogenesis in TRAMP mice. Int. J. Cancer, 124, 1693-1699.
23. Budin, S.B. et al. (2009) The effects of palm oil tocotrienol-rich fraction supplementation on biochemical parameters, oxidative stress and the vascular wall of streptozotocin-induced diabetic rats. Clinics (Sao Paulo), 64, 235-244.
24. Taridi, N.M. et al. (2011) Tocotrienol rich fraction (TRF) supplementation protects against oxidative DNA damage and improves cognitive functions in Wistar rats. Clin. Ter., 162, 93-98.
25. Chin, S.F. et al. (2008) Reduction of DNA damage in older healthy adults by Tri E Tocotrienol supplementation. Nutrition, 24, 1-10.
26. Kulkarni, S. et al. (2010) Gamma-tocotrienol protects hematopoietic stem and progenitor cells in mice after total-body irradiation. Radiat. Res., 173, 738-747.
27. Li, X.H. et al. (2010) Delta-tocotrienol protects mouse and human hematopoietic progenitors from gamma-irradiation through Erk/mTOR signaling. Haematologica, 95, 1996-2004.
28. Berbee, M. et al. Mechanisms underlying the radioprotective properties of c-tocotrienol: comparative gene expression profiling in tocol-treated endothelial cells. Genes Nutr, 171, 596-605.
29. Mahalingam, D. et al. Effects of supplementation with tocotrienol-rich fraction on immune response to tetanus toxoid immunization in normal healthy volunteers. Eur. J. Clin. Nutr, 65, 63-69.
30. Radhakrishnan, A.K. et al. (2009) Daily supplementation of tocotrienol-rich fraction or alpha-tocopherol did not induce immunomodulatory changes in healthy human volunteers. Br. J. Nutr., 101, 810-815.
31. Hafid, S.R. et al. (2010) Tocotrienols are good adjuvants for developing cancer vaccines. BMC Cancer, 10, 5.
32. Luk, S.U. et al. (2010) Gamma-tocotrienol as an effective agent in targeting prostate cancer stem cell-like population. Int. J. Cancer, 128, 2182-2191.
33. Perry, S.S. et al. (2007) Id1, but not Id3, directs long-term repopulating hematopoietic stem-cell maintenance. Blood, 110, 2351-2360.
34. Malanchi, I. et al. (2008) Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature, 452, 650-653.
35. Yap, W.N. et al. (2008) Gamma-tocotrienol suppresses prostate cancer cell proliferation and invasion through multiple-signalling pathways. Br. J. Cancer, 99, 1832-1841.
36. Yap, W.N. et al. (2010) Id1, inhibitor of differentiation, is a key protein mediating anti-tumor responses of gamma-tocotrienol in breast cancer cells. Cancer Lett., 291, 187-199.
37. Srivastava, J.K. et al. (2006) Tocotrienol-rich fraction of palm oil induces cell cycle arrest and apoptosis selectively in human prostate cancer cells. Biochem. Biophys. Res. Commun., 346, 447-453.
38. Selvaduray, K.R. et al. (2010) Palm tocotrienols inhibit proliferation of murine mammary cancer cells and induce expression of interleukin-24 mRNA. J. Interferon Cytokine Res., 30, 909-916.
39. Yap, W.N. et al. (2010) In vivo evidence of gamma-tocotrienol as a chemosensitizer in the treatment of hormone-refractory prostate cancer. Pharmacology, 85, 248-258.
40. Saito, Y. et al. (2010) Cytoprotective effects of vitamin E homologues against glutamate-induced cell death in immature primary cortical neuron cultures: tocopherols and tocotrienols exert similar effects by antioxidant function. Free Radic. Biol. Med., 49, 1542-1549.
41. Liu, H.K. et al. (2010) Inhibitory effects of gamma-tocotrienol on invasion and metastasis of human gastric adenocarcinoma SGC-7901 cells. J. Nutr. Biochem., 21, 206-213.
42. Chang, P.N. et al. (2009) Evidence of gamma-tocotrienol as an apoptosisinducing, invasion-suppressing, and chemotherapy drug-sensitizing agent in human melanoma cells. Nutr. Cancer, 61, 357-366.
43. Inokuchi, H. et al. (2003) Anti-angiogenic activity of tocotrienol. Biosci. Biotechnol. Biochem., 67, 1623-1627.
44. Shibata, A. et al. (2010) Suppression of gamma-tocotrienol on UVB induced inflammation in HaCaT keratinocytes and HR-1 hairless mice via inflammatory mediators multiple signaling. J. Agric. Food Chem., 58, 7013-7020.
45. Bi, S. et al. (2010) gamma-Tocotrienol modulates the paracrine secretion of VEGF induced by cobalt(II) chloride via ERK signaling pathway in gastric adenocarcinoma SGC-7901 cell line. Toxicology, 274, 27-33.
46. Weng-Yew, W. et al. (2009) Suppression of tumor growth by palm tocotrienols via the attenuation of angiogenesis. Nutr. Cancer, 61, 367-373.
47. Nakagawa, K. et al. (2004) DNA chip analysis of comprehensive food function: inhibition of angiogenesis and telomerase activity with unsaturated vitamin E, tocotrienol. Biofactors, 21, 5-10.
48. Wells, S.R. et al. Alpha-, gamma- and delta-tocopherols reduce inflammatory angiogenesis in human microvascular endothelial cells. J. Nutr. Biochem., 21, 589-597.
49. Yam, M.L. et al. (2009) Tocotrienols suppress proinflammatory markers and cyclooxygenase-2 expression in RAW264.7macrophages. Lipids, 44, 787-797.
50. Ghosh, S.P. et al. (2009) Gamma-tocotrienol, a tocol antioxidant as a potent radioprotector. Int. J. Radiat. Biol., 85, 598-606.
51. Berbee, M. et al. (2009) gamma-Tocotrienol ameliorates intestinal radiation injury and reduces vascular oxidative stress after total-body irradiation by an HMG-CoA reductase-dependent mechanism. Radiat. Res., 171, 596-605.
52. Kumar, K.S. et al. (2006) Preferential radiation sensitization of prostate cancer in nude mice by nutraceutical antioxidant gamma-tocotrienol. Life Sci., 78, 2099-2104.
53. Bao, S. et al. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 444, 756-760.
54. Blazek, E.R. et al. (2007) Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia. Int. J. Radiat. Oncol. Biol. Phys., 67, 1-5.
55. Chiou, S.H. et al. (2008) Identification of CD133-positive radioresistant cells in atypical teratoid/rhabdoid tumor. PLoS One, 3, e2090.
56. Phillips, T.M. et al. (2006) The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J. Natl Cancer Inst., 98, 1777-1785.
57. Kunnumakkara, A.B. et al. (2010) {Gamma}-Tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment. Cancer Res, 70, 8695-8705.
58. Yang, Z. et al. (2010) Synergistic actions of atorvastatin with gammatocotrienol and celecoxib against human colon cancer HT29 and HCT116 cells. Int. J. Cancer, 126, 852-863.
59. Bachawal, S.V. et al. (2010) Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cells. BMC Cancer, 10, 84.
60. Bachawal, S.V. et al. (2010) Combined gamma-tocotrienol and erlotinib/gefitinib treatment suppresses Stat and Akt signaling in murine mammary tumor cells. Anticancer Res., 30, 429-437.
61. Kannappan, R. et al. (2010) Gamma-tocotrienol promotes TRAIL-induced apoptosis through reactive oxygen species/extracellular signal-regulated kinase/p53-mediated upregulation of death receptors. Mol. Cancer Ther., 9, 2196-2207.
62. Kannappan, R. et al. (2010) {gamma}-Tocotrienol but not {gamma}-tocopherol blocks STAT3 cell signaling pathway through induction of protein tyrosine phosphatase SHP-1 and sensitizes tumor cells to chemotherapeutic agents. J. Biol. Chem, 285, 33520-33528.
63. Ahn, K.S. et al. (2007) Gamma-tocotrienol inhibits nuclear factor-kappaB signaling pathway through inhibition of receptor-interacting protein and TAK1 leading to suppression of antiapoptotic gene products and potentiation of apoptosis. J. Biol. Chem., 282, 809-820.
64. Theriault, A. et al. (2002) Tocotrienol is the most effective vitamin E for reducing endothelial expression of adhesion molecules and adhesion to monocytes. Atherosclerosis, 160, 21-30.
65. Campbell, S.E. et al. (2011) gamma-Tocotrienol induces growth arrest through a novel pathway with TGFbeta2 in prostate cancer. Free Radic. Biol. Med., 50, 1344-1354.
66. Shah, S. et al. (2004) Tocotrienol-induced caspase-8 activation is unrelated to death receptor apoptotic signaling in neoplastic mammary epithelial cells. Exp. Biol. Med. (Maywood), 229, 745-755.
67. Shin-Kang, S. et al. (2011) Tocotrienols inhibit AKT and ERK activation and suppress pancreatic cancer cell proliferation by suppressing the ErbB2 pathway. Free Radic. Biol. Med., 51, 1164-1174.
68. Nesaretnam, K. et al. (2010) Effectiveness of tocotrienol-rich fraction combined with tamoxifen in the management of women with early breast cancer: a pilot clinical trial. Breast Cancer Res., 12, R81.
69. Springett, G.M. et al. (2009) Vitamin E δ-Tocotrienol Administered to Subjects with Resectable Pancreatic Exocrine Neoplasia. National Institute of Health.
70. Springett, G.M. et al. (2011) A phase I dose-escalation study of the safety, PK, and PD of vitamin E d-tocotrienol administered to subjects with resectable pancreatic exocrine neoplasia. American Association for Cancer Research Annual Conference. Orange County Convention Center, Orlando, Florida, pp. 1299.
71. Ali, H. et al. (2010) Preparation, characterization, and anticancer effects of simvastatin-tocotrienol lipid nanoparticles. Int. J. Pharm., 389, 223-231.
72. Fu, J.Y. et al. (2011) Novel tocotrienol-entrapping vesicles can eradicate solid tumors after intravenous administration. J. Control. Release, 154, 20-26.
73. Elnagar, A.Y. et al. (2010) Design and preliminary structure-activity relationship of redox-silent semisynthetic tocotrienol analogues as inhibitors for breast cancer proliferation and invasion. Bioorg. Med. Chem., 18, 755-768.
74. Behery, F.A. et al. (2010) Redox-silent tocotrienol esters as breast cancer proliferation and migration inhibitors. Bioorg. Med. Chem., 18, 8066-8075.